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Aldosterone Modulates Cell Proliferation and Apoptosis in the 
Neonatal Rat Heart
In the present study, we investigated whether and how the mineralocorticoid receptor 
antagonist spironolactone affects cardiac growth and development through apoptosis and 
cell proliferation in the neonatal rat heart. Newborn rat pups were treated with 
spironolactone (200 mg/kg/d) for 7 days. The cell proliferation was studied by PCNA 
immunostaining. The treatment with spironolactone decreased proliferating myocytes by 
32% (P<0.05), and reduced myocytes apoptosis by 29% (P<0.05). Immunoblot and 
immunohistochemistry for the expression of p38, p53, clusterin, TGF-β2, and extracellular 
signal-regulated kinase were performed. In the spironolactone group, p38, p53, clusterin, 
and TGF-β2 protein expression was significantly decreased (P<0.05). These results indicate 
that aldosterone inhibition in the developing rat heart induces cardiac growth impairment 
by decreasing proliferation and apoptosis of myocytes. 
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
Our previous studies demonstrated that alterations in the renin 
angiotensin aldosterone system (RAAS), of the developing rat, 
affect cardiac and renal growth and development (1). To date, 
many studies have reported that RAAS plays a major role in the 
pathophysiology of the cardiovascular system (2, 3). Aldoste-
rone, the final product of the RAAS, has been highlighted as a 
potentially important component of the RAAS. In the cardiovas-
cular system, aldosterone modulates vascular tone by increas-
ing the pressor response to catecholamines or by upregulation 
of angiotensin II receptors (4), and it provides a homeostastic 
response to hypovolemia (5). However, aldosterone excess causes 
collagen deposition and remodeling in vessels (5). Therefore, 
excessive aldosterone secretion promotes perivascular and car-
diac fibrosis, myocyte hypertrophy and diastolic dysfunction 
that is independent of the other components of the RAAS by a 
variety of mechanisms (6). 
  The mineralocorticoid receptor antagonists, spironolactone 
and epelerenone, can prevent many of these deleterious effects, 
on the cardiovascular system. The mineralocorticoid receptor 
antagonist, spironolactone has been used to reverse these ad-
verse effects on the cardiovascular system in many patients with 
chronic heart disease such as congestive heart failure or myo-
cardial hypertrophy. Although several studies have investigated 
the role of aldosterone in the adult cardiovascular system (2, 3), 
relatively little attention has been focused on the role of aldo-
sterone in modulating cardiac growth during the perinatal pe-
riod. Aldosterone contributes to cardiomyocyte apoptosis both 
in vivo and in isolated cells (7). Apoptosis and cell proliferation 
are essential for normal cardiac development; dysregulation of 
this process can lead to a variety of cardiac diseases during post-
natal development. 
  As a final product of the RAAS, aldosterone is now recognized 
as an important modulator of myocyte apoptosis (8). Among 
the mitogen-activated protein kinase (MAPK) family members, 
p38 is activated by hemodynamic stress and cellular stress; it is 
thought to inhibit cell growth and induce apoptosis. However, 
the extracellular signal-regulated kinase (ERK) promotes cell 
proliferation and differentiation (9). Clusterin and p53 are apop-
tosis related molecules. Clusterin plays a major role in prevent-
ing apoptosis and p53 may enhance the renin-angiotensin sys-
tem and activates apoptosis (10). The transforming growth fac-
tor (TGF)-β is known as a multifunctional growth factor; it is in-
volved in modulating cell proliferation, differentiation and ex-
tracellular matrix formation (11).
  The intracellular molecular mechanisms involved in the con-
trol of cardiac growth and development, by aldosterone in vivo, 
have not been elucidated. Therefore, the present study was de-
signed to investigate the role of endogenous aldosterone in car-
diac growth and development, through apoptosis and cell pro-
liferation, in the neonatal rat heart. Sohn HJ, et al.  •  Aldosterone Modulates Cardiac Myocytes
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MATERIALS AND METHODS
Animal preparation 
Forty-five neonatal rat pups from five pregnant Sprague Dawley 
rats were breastfed by their own mothers throughout the study. 
The body weights were measured daily from birth. The rat pups 
were given a dose of 200 mg/kg of spironolactone (Sigma Chem-
ical Co., St. Louis, MO, USA) (S group) or normal saline (control 
group) through an orogastric tube. The dose of 200 mg/kg of 
spironolactone has been shown to block the effects on aldoste-
rone (7).
  This dose of spironolactone is known to protect cardiovascu-
lar system against the harmful effects of hemodynamic overload 
(12). The rats were sacrificed at 7 days of age. Their hearts were 
removed, weighed and harvested for this study. RNA analysis, 
protein assays, detection of apoptosis, and immunohistochem-
istry were performed. The Animal Care Committee of Korea Uni-
versity Guro Hospital approved the experimental protocol.
Immunohistochemical staining 
For assessment of the expression of p38, p53, clusterin, and TGF 
β-2, the harvested hearts were prepared in 10% formalin solu-
tion (Sigma Chemical Co.) and embedded in paraffin. The 
samples were then cut into 4-μm sections and the sections were 
deparaffinized with xylene, followed by rehydration in a descend-
ing series of ethanol concentrations. The endogenous peroxidase 
was quenched by 3% hydrogen peroxide in methanol for 15 min. 
The sections were incubated with primary antibodies against 
p38 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p53 (Cal-
biochem, Cambridge, USA), clusterin (Upstate Biotechnology, 
Incorporated, NY, USA), and TGF β-2 (Promega, Madison, WI, 
USA). After the incubation, the sections were washed twice for 
5 min in phosphate-buffered saline (PBS). The sections were 
then incubated for 30 min with secondary antibodies, washed 
in PBS and incubated for 50 min with Vectastain ABC reagent 
(Burlingame, CA, USA). The bound antibodies were detected 
using 3,3´-diaminobenzidine, which produces a brown color. 
The sections were counterstained with a 0.5% methyl green so-
lution (Trevigen, Gaithersburg, MD, USA), then the samples 
were dehydrated and mounted. After dehydration, we evaluat-
ed the specimens under the light microscope.
Detection of cell proliferation 
To assess cell proliferation, the harvested hearts were prepared 
in 10% formalin or Bouin solution (Sigma Chemical Co.), embed-
ded in paraffin, then immunohistochemical staining for the 
proliferating cell nuclear antigen (PCNA) was carried out. The 
PCNA-positive cells were detected using the avidin-biotin im-
munoperoxidase method (Vectastain ABC kit). The primary an-
tibodies were the monoclonal anti-mouse PCNA antibody (1:100 
dilutions, DAKO, Glostrup, Denmark) in the study group and 
PBS in the negative control group. Each slide was cross-stained 
with 0.5% methyl green solution (Trevigen). After dehydration, 
we compared the slides under the light microscope. The PCNA 
positive cells were evaluated by counting 50 areas (25×25 μm) 
and the average was calculated. The counts were carried out 
randomly throughout all the observed fields.
Detection of apoptosis 
To determine whether apoptosis is involved in the developing 
rat heart, we performed terminal deoxynucleotide transferase-
mediated nick-end labeling (TUNEL) staining for apoptotic cells 
in the heart of the control and spironolactone-treated group. 
Apoptotic nuclei were labeled using the TACS TM 2 TdT In situ 
Apoptosis Detection Kit (Trevigen, Gaithersburg, MD, USA). 
Tissues were fixed in 4% neutral buffered formalin for 4 hr at 4°C, 
dehydrated in graded alcohols and embedded in paraffin. The 
samples were then cut into 4 μm sections and dried onto silicon-
ized slides (Sigma Chemical Co.). The slides were deparaffinized 
and digested for 10 min with proteinase K (20 μg/mL) and the 
endogenous peroxidase activity was quenched by 2% hydrogen 
peroxide for 5 min. Samples were equilibrated using the provid-
ed buffer for 2 min and labeled with biotin dNTP mixtures, TdT, 
CoCl2, and a labeling buffer according to the manufacturer’s in-
structions. The samples were rinsed in PBS for 2 min, and treat-
ed with the provided Streptavidin-Horseradish Peroxidase De-
tection solution for 10 min and finally washed 2 times in PBS 
for 2 min each wash. The color was developed using 0.05% 3,3´- 
diaminobenzidine and 0.05% hydrogen peroxidase in PBS for 5 
min. The sections were rinsed in water and counter-stained in 
methyl green for 5 min, then the samples were dehydrated and 
mounted. After dehydration, we compared them under the light 
microscope. The positive apoptotic cells were counted in 50 ar-
eas (25×25 μm) and the average was calculated.  
Isolation of RNA and analysis of mRNA
Five hearts from the control group and the spironolactone-treat-
ed group were selected for RNA analysis and protein assays. Af-
ter removal from the rats, the cardiac tissue was frozen in liquid 
nitrogen and stored at -70°C. The total cellular RNA was isolat-
ed using the TRI-reagent (Molecular Research Center, Cincin-
nati, OH, USA) and homogenized with a tissue tearor (Model 
985-370, Biospec products, Bartlesville, OK, USA). Next, 37% 
chloroform (200 μL/mL TRI reagent) was added to the homog-
enates and centrifuged at 12,000 rpm for 15 min at 4°C separat-
ing the sample into three layers: RNA, DNA and protein materi-
al. The colorless clear upper layer was transferred into another 
Eppendorf tube, isopropanol was added, then left at room tem-
perature for 15 min centrifuged at 12,000 rpm for 10 min at 4°C 
until a white-colored cellular RNA pellet was isolated. The pellet 
was dried at room temperature for 5 min after washing in 75% 
ethanol and was dissolved in 25 μL Forma zol (Molecular Re-Sohn HJ, et al.  •  Aldosterone Modulates Cardiac Myocytes
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search Center) at 55°C in a heating block for 10 min and then 
stored at -70°C. The RNA was quantified spectrophotometrical-
ly at an absorbance of 260 nm.
cDNA synthesis by reverse transcription (RT) and PCR 
A cDNA Synthesis Kit (Boehringer Mannheim Corp., Indianap-
olis, IN, USA) was used to obtain 1 μg of oligo dT primed first 
strand cDNA from the RNA template. AMV reverse transcriptase 
was used for synthesis of the first strand cDNA for use in subse-
quent amplification reactions. The PCR reaction had a forward 
primer 5´-AATGCATCCTGCACCACCAA-3´ and a reverse prim-
er 5´-GTAGCCATATTCATTGTCATA-3´ for the GAPDH designed 
based on the DNA template from rats. In addition, 5´-CGGGTA–
CCGACAATGAGCTCCA-3´, 5´-GGCCGCGGCCACTTCTGCA–
GAC-3´ for clusterin, 5´-ATGTCTCAGGAGAGGCCCACGTT–
CT-3´, 5´-TCAGGAGTCCATTTCTTCTTGGTC-3´ for p38, 5´-CT-
GAGGTCGGCTCCGACTATACCACTATCC-3´, 5´-CTGATTCA–
GCTCTCGGAACATCTCGAAGCG-3´ for p53, 5´-CCTAGCCA–
GGGACGTTTTTC-3´, 5´-TAGACAGACTGAGCGCCACC-3´ for 
TGF β-2, all five 515, 310, 1080, 360, and 230 base pairs of the 
PCR products for each gene were obtained. The PCR reaction 
was carried out at different times and temperatures for each re-
action period using the Perkin Elmer Cetus DNA Thermal Cy-
cler (Model 2400, Foster City, CA, USA). These amplified PCR 
products were visible as a fluorescent band under UV rays, after 
agarose gel electrophoresis, at different time intervals and with 
ethidium bromide staining. Polaroid photographs were scanned 
using Epson GT-9500 (Seiko Corp, Nagano, Japan) and quanti-
tated by densitometry (Image PC alpha 9, NIH, Bethesda, MD, 
USA) and the values were revised based on the GAPDH.
Protein extraction
Alcohol (100%) was added to the interface and the organic phase 
remained from the RNA separation; then the DNA portion was 
precipitated after the sample was centrifuged at 5,000 rpm for 5 
min. Isopropanol was added to the remaining ethanol upper 
layer, which was centrifuged and dissolved in 0.3 M guanidine 
hydrochloride in 95% ethanol. Next, this layer was washed three 
times and a protein pellet was obtained. The extracted protein 
was dissolved in 1% SDS solution and preserved at -20°C. The 
Bradford method was used for the quantification of the protein.
Western blotting
To precipitate the DNA, the interface and the organic phase re-
maining after the RNA extraction were centrifuged at 5,000 rpm 
for 5 min at 4°C after treatment with 100% alcohol. A residual 
phenol-ethanol upper layer was added with isopropanol, cen-
trifuged and treated with 0.3 M guanidine hydrochloride dis-
solved in 95% ethanol. This layer was centrifuged at 10,000 rpm 
for 10 min at 4°C after incubation at room temperature for 15 
min, and this process was repeated three times. The sample was 
then washed to obtain a protein pellet. The extracted proteins 
were solubilized in 5×SDS loading buffer for 5 min at 95°C and 
separated by electrophoresis on 10% SDS-polyacrylamide gels 
under reducing conditions. Subsequently, the proteins were 
transferred to nitrocellulose membranes (Amersham Life Sci-
ence, Buckinghamshire, England). The nitrocellulose membranes 
were blocked in 5% skim milk with TBS-T (0.05% Tween 20 in 
50 mM Tris, 150 mM NaCl, 0.05% NaN3, pH 7.4) at room tem-
perature for 1 hr. The membranes were then incubated for 18 hr 
at 4°C with the respective primary antibodies against clusterin 
(1:100 dilution), p38 (1:1,000 dilution), p53 (1;200 dilution), TGF 
β-2 (1:200 dilution), ERK 1/2 (1:1,000 dilution), and JNK-2 
(1:500 dilution). Thereafter, the membranes were washed two 
times with TBS-T and incubated for 40 min with an anti-rabbit 
IgG (Amersham Life Science) at room temperature. After wash-
ing with TBS-T four times, the secondary antibody bound to the 
nitrocellulose was detected by incubation for 1 min with a detec-
tion reagent (Amersham Life Science) and then exposed to medi-
cal X-ray film (Agfa, Mortsel, Belgium) for 1 min. The film was 
developed by a FPM-3500 Fuji X-ray Film Processor (Fuji, Ota-
wara, Japan). The developed X-rays were scanned using the Ep-
son GT-9500 (Seiko Corp) and quantitated by densitometry (Im-
age PC α 9).
Statistical analysis
The data are presented as mean±SEM. The differences between 
the two groups were analyzed by the Student-Newman-Keuls 
test; a value of P<0.05 was considered statistically significant.
RESULTS 
On day 7, the average body weight was 13.1±1.4 g in the S group 
and 15.8±1.1 g in the control group. The heart weight was 0.08± 
0.01 g in the S group and 0.11±0.01 g in the control group. The 
heart weight/body weight ratio was 0.005±0.0009 in the S group 
and 0.007±0.0008 in the control group. The body weights, heart 
weights and heart weight/body weight ratio of the S group were 
significantly reduced compared to the control group (P<0.05). 
Proliferating cell nuclear antigen (PCNA) and apoptosis
  In PCNA immunostaining of the proliferating myocytes was 
lower in the myocardium of the neonatal rat heart in the S group 
compared to the control group. The PCNA-positive cells were 
28.1±6.61 in the control group and 19.18±2.09 in the S group in 
each of the 25×25 μm fields (P<0.05, Fig. 1). Myocyte apoptosis 
was detected using the toatal TUNEL technique. The myocyte 
apoptosis was lower in the myocardium of neonatal rat heart in 
the S group compared to the control group. Apoptotic nuclei were 
present in 0.71±0.18 of the control group and in 0.50±0.08 of the 
S group for each 25×25 μm field (P<0.05, Fig. 2). Spironolactone 
treatment decreased proliferating myocytes by 32% (P<0.05) and Sohn HJ, et al.  •  Aldosterone Modulates Cardiac Myocytes
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reduced myocyte apoptosis by 30% (P<0.05). However, apoptot-
ic nuclei accounted for only 2.5% of the relative fraction of cells 
undergoing proliferation in the present study. Finally, a net re-
duction of 32%, in cell proliferation, was observed in the S group 
compared to the control group.
Expression of p38 
The semiquantitative RT-PCR showed that p38/GAPDH mRNA 
expression was 0.77±0.1 in the control group and 0.87±0.12 in 
the S group (P=0.18; Fig. 3A). Immunoblot analysis revealed that 
the p38/tubulin protein expression was significantly decreased 
in the S group (1.04±0.15) compared to the control group (1.33± 
0.19; P<0.05; Fig. 3B). Immnohistochemically, there was no dif-
ference between control and spironolactone group. 
Expression of p53
The semiquantitative RT-PCR of p53/GAPDH mRNA expres-
sion was 1.02±0.11 in the control group and 1.13±0.08 in the S 
Fig. 3. Representative expressions of p38 mRNA and protein. (A) In immunoblot analysis, p38 mRNA amount is similar between the control and S groups. (B) p38/tubulin 
protein expression is decreased significantly in the S group compared with the control group, *P<0.05. 
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Fig. 2. Distribution of apoptotic cells in the myocardium. (A, B) Apoptotic cells (arrows) in the S group (B) are less than those in control group (A) (bar=25 µm). (C) Number of 
apoptotic cells in control group (black bar) is reduced in spironolactone group (white bar), measured by counting 50 areas, 25×25 µm, *P<0.05.
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proliferating myocytes (arrows) in the S group (B) are less than those in control group (A) (bar=25 µm). (C) Number of PCNA positive proliferating cells in control group (black 
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group (P=0.1; Fig. 4A). The immunoblot analysis revealed that 
the p53/tubulin protein expression was significantly decreased 
in the S group (0.71±0.11) compared to the control group (1.05± 
0.11; P<0.05; Fig. 4B). 
Expression of clusterin 
The semiquantitative RT-PCR showed that the clusterin/GAP-
DH mRNA expression was 0.90±0.22 in the control group and 
0.93±0.17 in the S group (P=0.83; Fig. 5A). Immunoblot analysis 
Fig. 4. Representative expressions of p53 mRNA and protein. (A) In immunoblot analysis, p53 mRNA amount is similar between the control and S groups. (B) p53/tubulin 
protein expression is decreased significantly in the S group compared with the control group, *P<0.05.
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revealed that the clusterin/tubulin protein expression was sig-
nificantly decreased in the S group (0.91±0.14) compared to the 
control group (1.12±0.07; P<0.05; Fig. 5B). Immunohistochemi-
cally, there was no difference between control and spironolac-
tone group. 
Expression of TGF β
The semiquantitative RT-PCR showed that the TGF β-2/GA–
PDH mRNA expression was 0.79±0.12 in the control group and 
0.58±0.13 in the S group (P<0.05; Fig. 6). Immunoblot analysis 
revealed that the TGF β-2/tubulin protein expression was sig-
nificantly decreased in the S group (0.83±0.15) compared to the 
control group (1.03±0.09; P<0.05: Fig. 6). Immunohistoche–mi-
cally, there was no difference between control and spironolac-
tone group (Fig. 6). Immunoblot analysis showed that the TGF 
β-1/tubulin protein expression was 0.96±0.02 in the control 
group and 0.92±0.06 in the S group. There was no detectable 
difference between the two groups (Fig. 7). 
Expression of ERK
The immunoblot analysis showed that the ERK-1/tubulin pro-
tein expression was 0.99±0.05 in the control group and 0.83±0.16 
in the S group (Fig. 8A), and the ERK-2/tubulin protein expres-
sion was 0.85±0.07 in the control group and 0.89±0.07 in the S 
group (Fig. 8B). There was no detectable difference between the 
two groups.  
Expression of JNK
Immunoblot analysis showed that the JNK-2/tubulin protein 
expression was 0.90±0.05 in the control group and 0.94±0.08 in 
the S group (Fig. 9). There was no detectable difference between 
the two groups. 
DISCUSSION 
The renin-angiotensin-aldosterone system (RAAS) plays an im-
portant role in regulating the cardiovascular system and is im-
portant in regulating the growth of the myocardium (13). An-
giotensin II, a product of the RAAS, causes an increase in blood 
Fig. 7. TGF β-1 protein expression in the developing rat heart. There is no difference 
between the control and S groups.
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Fig. 9. JNK-2 protein expression in the developing rat heart. There is no difference 
between the control and S groups.
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pressure through its vasoconstrictive effect. In addition, angio-
tensin II promotes cell growth via angiotensin II type I (AT1) re-
ceptors in cardiac myocytes, which cause inotropic and chro-
notropic changes and induce apoptosis in myocytes (14). A num-
ber of studies have demonstrated that alterations in the RAAS 
of developing rats affect cardiac growth and development (1, 15). 
A recent new wave of interest in aldosterone physiology has been 
generated by its role in cardiovascular homeostasis including 
blood-pressure homeostasis, myocardial fibrosis and remodel-
ing of blood vessels (6). In addition, recent studies have shown 
that aldosterone induces cardiomyocyte apoptosis (6, 14). Ac-
cording to Mano et al. (8), there are plasma membrane recep-
tors that are specific for aldosterone in myocytes. Activation of 
aldosterone receptors stimulates myocyte apoptosis through a 
cacineurin dependent mitochondrial death-signaling pathway. 
Chronic aldosterone receptor activation promotes vascular in-
flammation, vascular stiffness and perivascular collagen forma-
tion (16). The loss of myocytes by apoptosis in the dysfunctional 
heart results in reduced cardiac reserve capacity; this is one of 
the most important components of the pathogenesis of various 
cardiac diseases. Therefore, aldosterone excess has been shown 
to have a deleterious effect on the cardiovascular system (17).  
  However, there are few reports regarding the relationship be-
tween aldosterone and cardiac myocyte apoptosis and cell pro-
liferation in the developing heart, especially in the neonate. In 
this study, both cell proliferation and apoptosis were decreased 
in the spironolactone treated group. Blocking of aldosterone re-
duced the number of proliferating myocytes by 32% and de-
creased myocyte apoptosis by 29%. The decrease in cell prolif-
eration was counterbalanced by a reduction in myocyte apop-
tosis. However, the cells undergoing apoptosis accounted for 
only a minor fraction of the proliferating cells. Therefore, a net 
reduction of cell proliferation, in the cardiac myocytes, resulted 
from the blocking of aldosterone.  
  Although cardiomyocytes constitute only 30% of the ventric-
ular cellular population in the mature rodent, they may occupy 
up to 85% of the total volume of the ventricular myocardium 
(18). Therefore, the net reduction of cell proliferation in myo-
cytes, with aldosterone inhibition, may have contributed to the 
decrease in heart weight and heart weight to body weight ratio. 
The present in vivo animal study showed that aldosterone, the 
final product of RAAS, might play a role in cardiac growth in de-
veloping heart. The apoptotic and cell proliferation activity, in 
the cardiac myocytes, is mediated by several growth factors as-
sociated with apoptosis and cell proliferation. Among the MAPK 
signaling cascade, the p38 MAPK signaling pathway is activated 
in cardiac cells by hemodynamic stress or ischemia; it is thought 
to induce myocyte apoptosis, hypertrophy and fibroblast prolif-
eration. In some animal models using transgenic mice, p38 ac-
tivation resulted in interstitial fibrosis, cardiac hypertrophy and 
myocardial dysfunction (19). In the present study, p38 protein 
expression was significantly decreased by spironolactone; myo-
cyte apoptosis was lower in the myocardium of the spironolac-
tone treated group. These results suggest that p38 may be in-
volved in the aldosterone-related intracellular signaling path-
ways of myocyte apoptosis in the developing heart. 
  p53 is a tumor suppressor protein; it has been reported to up-
regulate the cellular renin-angiotensin system, potentiating the 
synthesis and release of the octapeptide angiotensin II, which 
induces myocyte apoptosis via the activation of surface AT1 re-
ceptors (20). In addition, p53 is a transcriptional regulator of the 
proapoptotic gene product Bax and antiapoptotic gene product 
Bcl-2 (21), the activation of p53 may upregulate Bax and down-
regulate Bcl-2 in myocytes (22). The decrease in the Bcl-2: Bax 
ratio and upregulation of the cellular renin-angiotensin system, 
by the activation of p53, is thought to trigger myocyte apoptosis 
(23). The results of this study showed that p53 protein expression 
was significantly decreased. However, the p53 mRNA expres-
sion was not significantly different in the spironolactone treated 
group compared to the control group. These findings suggest 
that p53 is involved in the intracellular signaling pathways of 
myocyte apoptosis in the developing rat heart. 
  Clusterin is a disulfide-linked heterodimeric glycoprotein, 
first isolated from ram rete testis fluid in 1983, it has been re-
ported to have a wide array of functions such as lipid transport, 
tissue remodeling, sperm maturation, and complement regula-
tion (24). Recent studies have demonstrated that clusterin has 
both anti-apoptotic and anti-proliferative activity (25). The role 
of clusterin may vary, but it may be anti-proliferative or anti-
apoptotic. If an anti-proliferative effect of clusterin dominates, 
this would render the cells susceptible to apoptosis. In this study, 
while there was no significant effect of spironolactone on myo-
cardial expression of clusterin mRNA, clusterin protein expres-
sion was significantly decreased by treatment with spironolac-
tone. These observations suggest that clusterin may participate 
in aldosterone-modulated intracellular signaling processes in 
myocyte apoptosis and proliferation.
  The protein expressions of p38, p53, clusterin were found to 
be decreased significantly in the spironolactone group, however, 
their mRNA expression levels showed no significant difference 
compared with the control group. We suspected that mRNA ex-
pressions of p38, p53, culsterin were slightly increased –although 
there was no statistical significance- as a secondary response to 
the decreased cellular proliferation and decreased protein ex-
pressions.
  Transforming growth factor-β (TGF-β) is a multifunctional 
growth factor molecule; it regulates cell proliferation and differ-
entiation in many different cell types (26). Recent studies have 
demonstrated that TGF-β promotes cardiac myocyte differenti-
ation from embryonic stem cells and upregulates cardiac tran-
scription factors (27). The TGF-β family of peptides has three iso-
forms of TGF-β (TGF–β1, -β2, and -β3). Among these isoforms Sohn HJ, et al.  •  Aldosterone Modulates Cardiac Myocytes
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of TGF-β, TGF-β2 participates in cardiac myocyte differentiation. 
TGF-β2-knockout mice have severe cardiovascular malforma-
tions (28). In the present study, we found that the TGF-β2 pro-
tein and mRNA expression were significantly decreased in the 
spironolactone-treated group compared to the control group. 
These results suggest that TGF-β2 is involved in aldosterone-re-
lated intracellular signaling pathways of cardiac growth and 
myocyte proliferation.  
  It is known that ERK and JNK are important regulators of car-
diac myocyte hypertrophic growth (29). ERK 1/2 activation is 
occurred to protect cardiomyocytes from apoptotic stimuli. 
However, there are no significant difference of ERK 1/2 expres-
sion between two groups in our experiment. This suggest that 
ERK singnaling pathway may not be associated with the action 
of spironolactone.
  The activation of JNK signaling pathway is associated with car-
diac hypertrophic response (30). However, there are no signifi-
cant difference of JNK expression between two groups in our 
experiment. This suggest that JNK singnaling pathway may not 
be associated with the action of spironolactone.
  In conclusion, the results of this study show an influential role 
of the aldosterone for the normal physiologic growth and devel-
opment of the rat heart. The blocking of aldosterone in the de-
veloping heart causes cardiac growth impairment by decreasing 
cell proliferation and apoptosis of cardiac myocytes. In addition, 
the expression of p38, p53, clusterin, and TGF-β2 proteins is de-
creased. These findings suggest that aldosterone is important for 
normal cardiac growth, and that p38, p53, clusterin, and TGF-β2 
may play an important role in the impairment of cardiac growth. 
In addition, aldosterone may post-transcriptionally modulate 
the expression of p38, p53, clusterin, and TGF-β2 during cardi-
ac development. Further studies are needed to investigate the 
intracellular signaling mechanisms involved in a variety of met-
abolic pathways responsible for reduction of cell proliferation 
and apoptosis by aldosterone inhibition in the developing heart. 
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